humanized anti-HER2 mAb-maytansine conjugate (Anhui Anke Biotechnology/WuXi PharmaTech)

N/A

Report date: 2025/03/20 15:00:26

Base Information

Drug Namehumanized anti-HER2 mAb-maytansine conjugate (Anhui Anke Biotechnology/WuXi PharmaTech)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAnhui Anke Biotechnology (Group) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuxi Apptec Co LtdAnhui Anke Biotechnology (Group) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A